Title: A unique spliced varicella-zoster virus latency transcript represses expression of the viral transactivator gene 61

Authors: Daniel P. Depledge^{1†}, Werner J.D. Ouwendijk^{2†}, Tomohiko Sadaoka^{3†}, Shirley E. Braspenning², Yasuko Mori³, Randall J. Cohrs⁴, Georges M. G. M. Verjans^{2,5†} and Judith Breuer^{1†}

Affiliations:

¹Division of Infection and Immunity, University College London, London, WC1E 6BT, United Kingdom.

²Department of Viroscience, Erasmus Medical Centre, 3015 CN, Rotterdam, The Netherlands.

³Division of Clinical Virology, Centre for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

⁴Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, 12700, USA; Department of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, Colorado, 12800, USA.

⁵Research Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, 30559, Hannover, Germany.

[#]Present address: Department of Microbiology, New York University, NY 10016, USA

***Correspondence to:** Judith Breuer at the Division of Infection and Immunity, University College London, WC1E 6BT, London, United Kingdom. Phone: +44 20 3108 2130 and Email: j.breuer@ucl.ac.uk /breuej@gosh.nhs.uk, and Georges M.G.M. Verjans at the Department of Viroscience, Erasmus Medical Center, 3015 CN, Rotterdam, The Netherlands. Phone: +31 10 7044066 and Email: g.verjans@erasmusmc.nl

[†]DPD, WJDO and TS contributed equally as first authors and [†]GMGMV and JB as last authors.

During primary infection, neurotropic alphaherpesviruses (α HVs) gain access to neurons in sensory and cranial ganglia establishing lifelong latent infection from which they can later reactivate to cause debilitating disease¹. For most α HVs, including the best-studied herpes simplex type 1 (HSV-1), viral latency is characterized by expression of a single or restricted set of transcripts that map antisense to the open reading frame (ORF) homologous to the major HSV immediate early viral transactivator, ICP0². These latency transcripts, either directly or through encoded miRNAs or proteins, repress expression of the ICP0 orthologues^{3–5}. The exception is varicella-zoster virus (VZV), an α HV which infects over 90% of adults and for which neither a canonical latency transcript^{1,6–8} nor a putative mechanism for repressing lytic transcription during latency have been identified. Here, we describe the discovery and functional characterization of a VZV latency transcript (VLT), that maps antisense to VZV ORF 61 (the VZV ICP0 homologue^{9,10}), and which is consistently expressed in neurons of latently infected human trigeminal ganglia (TG). VLT encodes a protein with late kinetics during lytic VZV infection *in vitro* and in zoster skin lesions. Whereas multiple alternatively spliced VLT isoforms are expressed during lytic VZV infection, a single unique VLT isoform that specifically suppresses ORF61 gene expression predominates in latently VZV-infected human TG. The discovery of VLT directly unifies the latent VZV transcription program with those of better-characterized α HVs, removing longstanding barriers to understanding VZV latency and paving the way for research into the development of vaccines that do not establish latency or reactivate, and drugs that eradicate latent VZV.

Primary VZV infection typically causes varicella (chickenpox), establishes a lifelong persistent infection in ganglia and reactivates in about one-third of latently infected individuals to cause herpes zoster (shingles), often accompanied by multiple serious neurological sequelae¹¹. Like other herpesviruses, lytic VZV infection is characterised by full viral gene expression occurring with temporally linked immediate-early (IE), early (E) and late (L) kinetics to generate infectious

virus progeny^{12,13}. By contrast VZV gene expression during latency remains poorly defined^{6,8,14–16}. A lack of appropriate animal¹⁷ and *in vitro*^{18,19} models has led to VZV latency being studied in naturally infected human TGs recovered at post-mortem. Using PCR primers targeting all canonical VZV genes, only ORF63 is occasionally detected in TGs with PMI <9 hrs⁸, whereas multiple virus transcripts of different kinetic classes are observed in human TGs with PMI >9 hrs^{6,8,15}. Moreover, reports of viral protein detection by immunohistochemistry (IHC) have been largely attributed to the presence of non-VZV antibodies¹⁶. The lytic VZV gene ORF63, although conserved is not expressed by other latent α HVs and does not share the characteristics of other canonical α HV latency transcripts.

The aim of this study was to use RNA sequencing (RNA-seq) to map the latent transcriptome of VZV in VZV and HSV-1 co-infected human TG harvested with short PMI (≤ 8 hrs). Because both viruses are estimated to establish latency in <1-5% of TG neurons¹, we increased the sensitivity of our RNA-seq approach by introducing a hybridization-based target-enrichment step for viral nucleic acids using custom overlapping 120-nucleotide RNA probes^{20,21}. Co-enriching for HSV-1 transcripts allowed us to benchmark our findings against those for HSV-1 latency which has been extensively studied¹. Our experimental approach was validated using lytically VZV- or HSV-1-infected human retinal pigmented epithelial (ARPE-19) cells to demonstrate detection of all currently annotated VZV and HSV-1 genes at high specificity and sensitivity (Fig. 1, and Supplementary Fig. 1). RNA-seq of unenriched RNA libraries from two dually infected TGs (donors 1 and 2, Supplementary Tables 1 and 2), selected for polyadenylated transcripts or ribosomal RNA-depleted total RNA (Supplementary Fig. 2), confirmed expression of the stable 1.5/2.0-kb latency-associated transcript (LAT)-derived introns, the hallmark of HSV-1 latency²². Enrichment for polyadenylated HSV-1 sequences in the same TGs, and five additional dually infected TGs (donors 1-7, Supplementary Tables 1 and 2), revealed both LAT introns and the near-complete 8.3-kb full-length LAT transcript from which

they derive, but no other viral transcripts (Supplementary Figs. 3 and 4). The latency-associated miRNAs (mir-H2, mir-H3, mir-H4, mir-H6, mir-H7 and mir-H14)⁵ were also detected in three TGs (donors 1, 3 and 8) selected for and analysed by miRNA sequencing of unenriched RNA libraries (Supplementary Fig. 5). These data illustrate the high specificity and sensitivity of our target-enriched RNA-seq methodology and clearly demonstrate that the HSV-1 latency transcriptome in human TG is limited to the LATs and encoded miRNAs.

While no VZV transcripts could be identified in non-enriched TG RNA samples (Supplementary Fig. 6), enrichment for VZV sequences in polyadenylated RNA revealed the presence of a novel 496-nucleotide multi-exon transcript expressed partially antisense to VZV ORF61 in all seven TGs analysed (donors 1-7; Fig. 1, Supplementary Figs. 6 and 7, Supplementary Tables 1 and 2). Manual inspection of the VZV sequence read data, combined with *de novo* transcript reconstruction, revealed five distinct exons (Fig. 1 and Supplementary Fig. 8a), two of which encode cleavage factor I-binding motifs (TGTA), while the most 3' exon contained a canonical polyadenylation signal site (AAUAAA) (Supplementary Fig. 8b). We term this novel spliced transcript the VZV latency transcript (VLT). Except for ORF63 transcripts detected in six of seven TGs (donors 2-7), no other VZV transcripts (Fig. 1b and Supplementary Fig. 7) or miRNAs were detected in human TGs (data not shown). VLT was also transcribed in lytically VZV-infected ARPE-19 cells (Fig. 1b and Supplementary Fig. 7), enabling rapid amplification of cDNA ends (RACE) to confirm 5' and 3' transcript boundaries. Unlike the single VLT isoform detected in latently VZV-infected human TG (Fig. 2a), gene transcription from the VLT locus appears extremely complex during lytic VZV infection, with additional upstream exons or alternative splicing in exons 3 and 4 (Fig. 2b). RT-qPCR did not detect any of the three most abundant lytic VLT isoforms (each of which uses a different upstream exon) in latently VZV-infected TGs (Fig. 2c). Neither were additional upstream exons or alternative splicing of exons 3 and/or 4 evident in human TG-derived VZV RNA from re-examination of the RNA-seq data.

Thus, a unique VLT isoform is selectively expressed in latently VZV-infected human TG with short PMI.

To confirm that VLT expression is a general feature of VZV latency, we analysed TG specimens from 18 individuals (donors 1-18, Supplementary Table 1) for the presence of VZV and HSV-1 DNA and transcripts by qPCR and reverse transcriptase-qPCR (RT-qPCR). Thirteen TG were co-infected with VZV and HSV-1, while the remaining TG contained only VZV (donors 10 and 12) or HSV-1 (donors 16 – 18), (Supplementary Table 1). Fourteen of 15 (93%) VZV nucleic acid-positive (VZV^{POS}) TGs expressed VLT and 9 of 15 (60%) VZV^{POS} TGs co-expressed ORF63 mRNA at lower levels relative to VLT (Fig. 2d, Supplementary Fig. 9a and Supplementary Table 1). VLT levels correlated significantly with ORF63 transcript levels (Fig. 2e and Supplementary Fig. 9b), but not with VZV DNA load or PMI excluding the possibility of viral reactivation after death (Supplementary Figs. 9c and d)⁸.

Next, we investigated the expression and localization of VLT, and as a control VZV ORF63, in latently VZV-infected TGs (n=12) and two VZV naïve foetal dorsal root ganglia (DRG) by *in situ* hybridization (ISH). VLT and ORF63 transcripts were localized to both the neuronal nucleus and cytoplasm of distinct neurons in latently VZV-infected TG, but not in uninfected DRG (Fig. 2f-i, Supplementary Figs. 10 and 11). More TG neurons expressed VLT ($0.49 \pm 0.20\%$; mean $\pm$ SD) than ORF63 transcript ($0.36 \pm 0.16\%$) (Fig. 2f). RNase but not DNase treatment abolished ORF63- and VLT-specific ISH staining (Supplementary Fig. 10), confirming detection of VZV transcripts and not viral genomic DNA. Although previous reports suggest that TG neurons are latently infected by VZV and HSV-1 at similar frequencies²³, both RT-qPCR and ISH (Supplementary Table 1, Supplementary Fig. 11) revealed a much higher abundance and prevalence of HSV-1 LAT compared to VLT and VZV ORF63 RNA in human TG specimens.

In silico translation of the VLT isoform expressed in human TG predicted a 137-amino acid protein (pVLT), with a start codon and polyadenylation site/stop codon in exons 2 and 5, respectively (Supplementary Fig. 8b). A polyclonal pVLT-specific antibody, generated against the first 19 N-terminal residues of pVLT, confirmed pVLT expression in the nucleus and cytoplasm of VLT-transfected cells and its predominantly nuclear expression in lytically VZV-infected ARPE-19 cells (Fig. 3a and b, Supplementary Figs. 8c and 12). In lytically VZV-infected ARPE-19 cells, pVLT co-localized with nuclear-expressed ORF62 protein (IE62), but not with cytoplasmically expressed glycoprotein E (Fig. 3b, Supplementary Fig. 12). The kinetic class of VLT was determined by RT-qPCR in VZV-infected ARPE-19 cells cultured in the presence or absence of phosphonoformic acid (PFA), a broad-spectrum herpesvirus DNA polymerase inhibitor²⁴. Whereas no effect on ORF61 (IE gene) and ORF29 (E gene) transcription was observed, ORF49 (leaky-L gene) transcription was markedly reduced in PFA-treated VZV-infected cells (Fig. 3c). PFA blocked VLT expression completely (Fig. 3c), demonstrating that VLT transcription follows a truly late kinetic pattern *in vitro*. Finally, shingles skin biopsies were assayed for expression of VLT and pVLT. ISH revealed VLT expression throughout the affected epidermis and dermis surrounding skin vesicles (Fig. 3d), while IHC analyses of consecutive sections for VZV ORF63 protein (IE63) and pVLT indicated co-expression in the same skin areas, but not in healthy control skin (Fig. 3e, Supplementary Fig. 13). Neither pVLT- nor IE63-specific IHC signal was detected in latently VZV-infected human TG sections (data not shown).

Because VLT is partially antisense to VZV gene ORF61, a major viral transactivator and α HV ICP0 homologue⁹, we tested whether VLT repressed expression of ORF61 in VLT-transfected ARPE-19 cells. VLT expression significantly reduced ORF61, but not ORF62 and ORF63 transcript levels, in cells co-transfected with all four VZV genes (Fig. 4a). Western blot analysis confirmed that VLT diminishes IE61 but not IE62, IE63 and α -tubulin protein abundance in co-transfected cells (Fig. 4b). Mutation of the pVLT start codon from ATG to ATA

(Supplementary Fig. 8b) resulted in loss of pVLT expression in co-transfected ARPE-19 cells, but did not abolish the inhibitory effect of VLT on ORF61 transcript and protein (IE61) expression in co-transfected cells (Fig. 4b and c, Supplementary Fig. 14). The data implicate VLT, but not pVLT, in the selective repression of VZV ORF61 gene expression.

In this study, we identified a novel and unique, spliced VZV transcript, VLT, which is consistently and selectively expressed in latently VZV-infected human TG neurons. The VLT locus, including splice donor/acceptor sites and pVLT coding sequence, is highly conserved among wild-type and vaccine strains of VZV (Supplementary Table 4). A feature shared between well-characterized latency transcripts of other α HVs, notably HSV-1 and bovine herpesvirus 1, is their ability to encode repressive miRNAs^{5,25}. However, consistent with previous analyses of human TG²⁶, we found no evidence of miRNAs encoded within VLT or the wider viral genome. In further contrast to other α HVs, latent VZV also transcribes ORF63 in a subset of latently infected TGs, suggesting a role for this gene in latency or early reactivation. We also find no evidence for expression of other VZV genes during latent infection. Moreover, unlike HSV-1 LAT, VLT encodes a protein that is expressed with true late kinetics in lytically VZV-infected cells *in vitro* and in shingles skin lesions. Whereas the function of pVLT remains unclear, we showed that VLT specifically suppresses expression of VZV IE61, a homolog of HSV-1 ICP0 and a promiscuous transactivator of lytic viral promoters¹⁰. Although VZV disease is now much reduced due to effective vaccines^{27–29}, latent persistence of the VZV vOka vaccine strain, that like wild-type VZV can reactivate later in life, will necessitate continuing lifelong surveillance and potentially revaccination³⁰. With our findings the field is now better positioned to understand the molecular pathways by which VZV establishes and maintains latency. This information will be critical for the future development of measures to enhance control of this ubiquitous human herpesvirus.

References

1. Kennedy, P. G. E., Rovnak, J., Badani, H. & Cohrs, R. J. A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. *J. Gen. Virol.* **96**, 1581–602 (2015).
2. Jones, C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. *Clin. Microbiol. Rev.* **16**, 79–95 (2003).
3. Nicoll, M. P. *et al.* The HSV-1 Latency-Associated Transcript Functions to Repress Latent Phase Lytic Gene Expression and Suppress Virus Reactivation from Latently Infected Neurons. *PLoS Pathog.* **12**, e1005539 (2016).
4. Jones, C., da Silva, L. F. & Sinani, D. Regulation of the latency-reactivation cycle by products encoded by the bovine herpesvirus 1 (BHV-1) latency-related gene. *J. Neurovirol.* **17**, 535–45 (2011).
5. Umbach, J. L. *et al.* MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature* **454**, 780–783 (2008).
6. Cohrs, R. J. & Gilden, D. H. Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. *J. Virol.* **81**, 2950–2956 (2007).
7. Kennedy, P. G., Grinfeld, E. & Gow, J. W. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. *Proc. Natl. Acad. Sci.* **95**, 4658–62 (1998).
8. Ouwendijk, W. J. D. *et al.* Restricted varicella-zoster virus transcription in human trigeminal ganglia obtained soon after death. *J. Virol.* **86**, 10203–6 (2012).
9. Wang, L., Sommer, M., Rajamani, J. & Arvin, A. M. Regulation of the ORF61 Promoter and ORF61 Functions in Varicella-Zoster Virus Replication and Pathogenesis. *J. Virol.* **83**, 7560–7572 (2009).
10. Moriuchi, H., Moriuchi, M., Straus, S. E. & Cohen, J. I. Varicella-zoster virus (VZV) open

- reading frame 61 protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA. *J. Virol.* (1993).
11. Gilden, D., Cohrs, R. J., Mahalingam, R. & Nagel, M. A. Neurological disease produced by varicella zoster virus reactivation without rash. *Curr. Top. Microbiol. Immunol.* **342**, 243–53 (2010).
 12. Reichelt, M., Brady, J. & Arvin, A. M. The Replication Cycle of Varicella-Zoster Virus: Analysis of the Kinetics of Viral Protein Expression, Genome Synthesis, and Virion Assembly at the Single-Cell Level. *J. Virol.* (2009). doi:10.1128/JVI.02137-08
 13. Pellet, P. E. & Roizman, B. Chapter 59: Herpesviridae. in *Fields Virology* (eds. Knipe, D. M. & Howley, P. M.) 2770 – 2802 (Lippincott Williams & Wilkins, 2013).
 14. Cohrs, R. J., Gilden, D. H., Kinchington, P. R., Grinfeld, E. & Kennedy, P. G. E. Varicella-zoster virus gene 66 transcription and translation in latently infected human Ganglia. *J. Virol.* **77**, 6660–5 (2003).
 15. Nagel, M. A. *et al.* VZV Transcriptome in Latently Infected Human Ganglia. *J. Virol.* **85**, JVI-01862 (2010).
 16. Zerboni, L. *et al.* Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons. *J. Virol.* **86**, 578–83 (2012).
 17. Haberthur, K. & Messaoudi, I. Animal Models of Varicella Zoster Virus Infection. *Pathogens* (2013). doi:10.3390/pathogens2020364
 18. Sadaoka, T. *et al.* In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency. *Proc. Natl. Acad. Sci.* 201522575 (2016). doi:10.1073/pnas.1522575113
 19. Markus, A., Lebenthal-Loinger, I., Yang, I. H., Kinchington, P. R. & Goldstein, R. S. An In Vitro Model of Latency and Reactivation of Varicella Zoster Virus in Human Stem Cell-Derived Neurons. *PLoS Pathog.* **11**, 1–22 (2015).

20. Depledge, D. P. *et al.* Specific Capture and Whole-Genome Sequencing of Viruses from Clinical Samples. *PLoS One* **6**, (2011).
21. Depledge, D. P. *et al.* Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans. *Mol. Biol. Evol.* **31**, 397–409 (2014).
22. Stevens, J. G., Wagner, E. K., Devi-Rao, G. B., Cook, M. L. & Feldman, L. T. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. *Science* (80-.). **235**, 1056–1059 (1987).
23. Wang, K., Lau, T. Y., Morales, M., Mont, E. K. & Straus, S. E. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level. *J. Virol.* (2005). doi:10.1128/JVI.79.22.14079-14087.2005
24. Cheng, Y. C. *et al.* Mode of action of phosphonoformate as an anti-herpes simplex virus agent. *Biochim. Biophys. Acta* **652**, 90–8 (1981).
25. Jaber, T., Workman, A. & Jones, C. Small Noncoding RNAs Encoded within the Bovine Herpesvirus 1 Latency-Related Gene Can Reduce Steady-State Levels of Infected Cell Protein 0 (bICP0). *J. Virol.* **84**, 6297–6307 (2010).
26. Umbach, J. L., Nagel, M. a, Cohrs, R. J., Gilden, D. H. & Cullen, B. R. Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. *J. Virol.* **83**, 10677–10683 (2009).
27. Oxman, M. N. *et al.* A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. *N. Engl. J. Med.* **352**, 2271–2284 (2005).
28. Takahashi, M. *et al.* Live Vaccine Used To Prevent the Spread of Varicella in Children in Hospital. *Lancet* **304**, 1288–1290 (1974).
29. Cunningham, A. L. *et al.* Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. *N. Engl. J. Med.* (2016). doi:10.1056/NEJMoa1603800

30. Galea, S. A. *et al.* The Safety Profile of Varicella Vaccine: A 10-Year Review. *J. Infect. Dis.* **197**, S165–S169 (2008).

Acknowledgements

DPD is supported by a New Investigator Award from the Medical Research Foundation (UK MRC) and a small grant provided by the Daiwa Foundation. JB was partially funded by the UCL/UCLH Biomedical Research Centre (BRC). TS received funding from the Takeda Science Foundation, Japan Society for the Promotion of Science (JSPS KAKENHI JP17K008858) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT KAKENHI JP17H05816) and was, in part, supported by a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT of Japan (JP16H06429 and JP16K21723). WJDO, RJC and GMGMV were partly supported by National Institutes of Health grant AG032958. GMGMV received funds from the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony (Germany). RJC was additionally supported by Public Health Service grant NS082228. We acknowledge support from the Medical Research Council and BRC for the UCL/UCLH Pathogen Sequencing Pipeline as well as the UCL Legion High Performance Computing Facility, and associated support services, in the completion of this work. The authors would like to acknowledge Sarah Getu and Suzanne van Veen for technical assistance (Dept. of Viroscience, Erasmus MC, Rotterdam, The Netherlands) and the whole team of the Netherlands Brain Bank (www.brainbank.nl) for their work and contributions.

Author contributions

DPD, WJDO, TS, GMGMV and JB designed the study. DPD, WJDO, TS and SEB performed experiments. All authors analysed and critiqued the data. DPD, WJDO, TS, RJC, GMGMV and JB wrote the manuscript.

Figure Legends

ganglia (TG) (Supplementary Table 1). **a**, Circos plots of the VZV genome [purple band; sense and antisense open reading frames (ORFs) indicated as red and blue blocks, respectively], with internal tracks revealing the lytic (left) and latent (right) transcriptomes using unenriched (grey track, left panel) and VZV-enriched (black tracks, left and right panels) libraries. Right panel: latent VZV transcriptome of seven TG, with each track depicting a single specimen. Peaks facing outward from the center indicate reads mapping to the sense strand, while peaks facing inward originate from the antisense strand. The y-axis is scaled to maximum read depth per library in all cases. **b**, Linear representation of the varicella latency transcript (VLT) genomic region (black lines in **a**), with blue and yellow tracks depicting VZV-enriched mRNA-Seq reads originating from the sense and antisense strand, respectively. Unenriched mRNA-Seq tracks for ARPE-19 cells, and TGs 1 and 2, are superimposed and shown in light blue (sense) or yellow (antisense), with overlapping regions in medium-blue and orange, respectively. No VZV-mapping reads were obtained from unenriched sequence datasets generated from TGs 1 and 2. VZV genome coordinates are shown the VZV reference strain Dumas (NC_001348.1); blue and red arrows indicate previously described VZV ORFs, and light blue boxes indicate the five VLT exons. Paired-end read datasets were generated with read lengths of 2x34 bp (ARPE-19) or 2x76 bp (TG1 and TG2) or 2x151 bp (TG3 - TG7).

Figure 2 | Prevalence of VZV ORF63 transcript and a unique VLT isoform in latently VZV-infected human TG. **a**, In latently VZV-infected human TG, selected paired-end reads originating from VLT sequence fragments that span multiple exons evidenced the usage of conserved splice sites between exons. Grey boxes connected by horizontal black lines indicate individual read pairs (1 – 3 per line) and show mapping regions (corresponding to the blue VLT exons), while black lines indicate skipped (spliced) regions. Data from one of four TG analysed are shown. **b**, In lytically VZV-infected MeWo cells, Sanger sequencing of amplicons generated through rapid amplification of cDNA ends (RACE) revealed multiple VLT isoforms in these cells. Grey filled boxes indicate VLT exons with splice junctions shown by horizontal black lines. Red

boxes indicate most abundant groups of 5' end splice junctions (boxes A – C), for which the percentage of recombinant *E. coli* colonies was 35% (box A), 19% (box B) and 15% (box C), as determined by colony sequencing of *E. coli* transformed with plasmids encoding PCR products spanning the 5' end to VLT exon 5 (n=29). **c**, Detection of ORF63 and VLT isoforms in lytically VZV-infected ARPE-19 cells (red) and latently VZV-infected human TG (blue; n=19 TG) (Supplementary Table 1), using primers/probes spanning VLT exons 3→4, A→1, B→1 and C→1 (Supplementary Table 5). Data represent mean ($\pm$ standard error mean; SEM) relative transcript levels normalized to β -actin RNA abundance. nd, not detected. **d**, Levels of paired ORF63 transcript and VLT (primers/probe spanning VLT exons 2→3) in the same VZV nucleic acid positive human TG (VZV^{POS}; n=15), as determined by reverse transcription-linked quantitative PCR (RT-qPCR). *** $p < 0.001$; Wilcoxon signed rank test. **e**, Correlations (Spearman) between relative ORF63 RNA and VLT levels in VZV^{POS} human TG (n=15), as determined based on RT-qPCR. **f-i**, Analysis of ORF63 RNA and VLT abundance in latently VZV-infected TG (n=12) by *in situ* hybridization (ISH). **f**, Frequency of neurons positive by ISH for ORF63 RNA and VLT in consecutive TG sections of the same donor. * $p < 0.05$; paired Student's t-test. **g**, Nuclear and cytoplasmic ORF63 RNA and VLT expression in consecutive TG sections from individual donors. ns, not significant. **h**, Representative images of human TG sections using probes specific for ORF63 and VLT. **i**, Absence of ORF63 RNA and VLT ISH signal in two VZV naïve human fetal dorsal root ganglia. In **h** and **i**, nuclei were stained with hematoxylin. Magnification: 400X, Inset: 400X magnification and 3X digital zoom.

Figure 3 | Expression and localization of VLT protein *in vitro* and *in vivo*. **a**, Representative confocal microscopy image of ARPE-19 cells at 48 hr post-transfection with C-terminal FLAG-tagged VLT (pVLT-FLAG) expression plasmid. pVLT-FLAG was detected with antibodies directed to FLAG (red) and VLT protein (pVLT; green). Magnification: 1000X and 2X digital zoom. Bars= 5 μm. **b**, Representative confocal microscopy images of VZV strain pOka-infected ARPE-19 cells at 5 days post-infection, stained for pVLT (green) and VZV ORF62 protein (IE62; red) (left panel), or pVLT (green) and VZV glycoprotein E (gE; red) (right panel). Magnification: 1000X. Bars=10 μm. In **a** and **b**, nuclei were stained with Hoechst 33342 (blue) and images are representative of results from 3 independent experiments. **c**, RT-qPCR quantitation of VZV ORF61, ORF29, ORF49 RNA and VLT levels in VZV pOka-infected ARPE-19 cells cultured with (PFA+) and without phosphonoformic acid (PFA-) for 24 hr. Data represent mean (± SEM) fold-change in gene expression, using the respective 'PFA-' value as a calibrator, from four independent experiments. *** $p < 0.001$; Wilcoxon signed rank test. **d**, Detection of VLT (red) in a human herpes zoster (HZ) skin lesion by *in situ* hybridization. Magnification: 100X. Inset: 400X

and 2X digital zoom. **e**, Consecutive HZ skin sections stained immunohistochemically for ORF63 protein (IE63; brown) and pVLT (brown) (left and middle panels) and sections from unaffected control skin stained for pVLT (right panel). Magnification: 200X. Inset: 400X. Images in **d** and **e** are representative of five HZ skin biopsies stained.

Figure 4 | Selective repression of VZV ORF61 gene expression by VLT. ARPE-19 cells were transfected with plasmids encoding FLAG-tagged VLT (VLT_{ATG}), mutated VLT in which the ATG start codon was replaced by ATA sequence (VLT_{ATA}) (Supplementary Fig 8), or empty control plasmid (empty), in combination with plasmids encoding ORF61, ORF62 and ORF63. **a**, Analysis of VZV ORF61, ORF62, ORF63 and human β -actin RNA by RT-qPCR. Data represent mean ($\pm$ SEM) fold-change in gene expression using the empty vector to calibrate ORF61, ORF62 and ORF63, or using VLT_{ATA} to calibrate VLT_{ATG}. Data are from two independent experiments performed in duplicate. nd, not detected. *** $p < 0.001$; one-way ANOVA with Bonferroni's correction for multiple comparisons. **b**, Western blot analysis using antibodies directed to proteins encoded by VZV ORF61 (IE61), ORF62 (IE62), ORF63 (IE63), VLT (pVLT) and FLAG-tagged pVLT and α -tubulin. None, untransfected ARPE-19 cells. Images are representative of 4 independent experiments. **c**, Confocal microscopy image of cells stained with antibodies directed to FLAG (red) and pVLT (green), and nuclei stained with Hoechst (blue). Magnification: 2000X. Bars=5 μ m. Images are representative of two independent experiments.

List of Supplementary Materials

Supplementary Fig 1 – 14

Table S1 – S5

Methods

References (31 – 48)

Supplementary Figures

Supplementary Figure 1 | Unbiased enrichment of HSV-1 and VZV transcriptomes in lytically virus-infected human ARPE-19 cells. **a**, Transcript per million (TPM) counts were generated for all canonical ORFs of VZV (left) and HSV-1 (right) in VZV/HSV-1–enriched and unenriched sequence datasets derived from poly-A-selected RNA extracted from lytically virus-infected ARPE-19 cells. R^2 correlation scores are shown in red. **b** and **c**, Mean read depths across iterative 25-nt windows for VZV (left) and HSV-1 (right) genomes were plotted using a log scale for VZV/HSV-1–enriched and unenriched sequence datasets derived from poly-A-selected RNA. Forward strand (**b**) and reverse strand (**c**) show a high correlation ($R^2 > 0.91$) between enriched and unenriched datasets.

Supplementary Figure 2 | Comparison of unenriched and enriched poly-A-selected and rRNA-degraded HSV-1 transcriptome in latently HSV-1-infected human TG. RNA-Seq read data presented in a linear format along the entire 152-kb HSV-1 genome for TG specimens from donors 1 and 2 (Supplementary Table 1) and for lytically HSV-1-infected ARPE-19 cells. Each track depicts either unenriched or enriched poly-A-selected (pA) or rRNA-degraded (rRNA) HSV-1 transcriptome. Blue and red tracks represent read data originating from the sense and antisense strand, respectively. Y-axis values indicate read depth. Previously described HSV-1 ORFs within this locus (blue and red arrows) are shown. Paired-end read datasets were generated with read lengths of 2x34 bp (ARPE-19 cells) or 2x76 bp (TG1 and TG2).

Supplementary Figure 3 | The latent and lytic transcriptome of HSV-1. RNA-Seq read data presented in a linear format along the entire 152-kb HSV-1 genome for all seven TG specimens separately and lytically HSV-1-infected ARPE-19 cells. Each track depicts the poly-A-selected, HSV-1 enriched transcriptome. Blue and red tracks represent read data originating from the sense and antisense strand, respectively. Y-axis values indicate read depth (label figure itself). Unenriched tracks superimposed on TG1, TG2 and ARPE-19 are shown in light blue (sense) or orange (antisense). Previously described HSV-1 ORFs are indicated by blue (sense strand) and red (antisense strand) arrows, while the HSV-1 latency-associated transcripts (LATs) are indicated by green boxes. Paired-end read datasets were generated with read lengths of 2x34 bp (ARPE-19), 2x76 bp (TG1 and TG2) or 2x151 bp (TG3 - TG7).

Supplementary Figure 4 | Lytic and latent transcriptome across the HSV-1 LAT locus.

RNA-Seq read data presented in a linear format across the HSV-1 LAT region (sense strand coordinates 118,000-128,000 bp of HSV-1 reference strain 17; NC_001806) for each of the HSV-1-enriched transcriptomes of all seven TG specimens separately and for lytically HSV-1-infected ARPE-19 cells. Each track depicts poly-A-selected, HSV-1 enriched transcriptomes. Blue and yellow tracks represent read data originating from the sense and antisense strand, respectively. Y-axis values indicate read depth. Unenriched tracks superimposed on TG1, TG2 and ARPE-19 are shown in light blue (sense) or orange (antisense). Previously described ORFs within this HSV-1 locus (red blocks), miRNAs (orange blocks), predicted LAT-encoded ORFs (green blocks²), LAT-encoded small RNAs (purple blocks) and LAT (blue boxes) are scaled representatively.

Supplementary Figure 5 | HSV-1 miRNAs detected in latently HSV-1-infected human TG.

a, Five canonical miRNAs (miR-H2, 3, 4, 7 and 8) are encoded within HSV-1 LAT, while a sixth (miR-H14) is encoded antisense to miR-H7. Two additional miRNAs (miR-H1 and H6) expressed during latency are encoded just upstream of the 5' end of LAT. **b**, miRNA-Seq of TG1, TG3 and TG5 confirmed transcription of these and the absence of remaining miRNAs encoded in the wider HSV-1 LAT locus (and wider genome, data not shown). Only miRNAs producing >5 reads are shown.

Supplementary Figure 6 | Comparison of unenriched and enriched poly-A-selected and rRNA-degraded VZV transcriptome in latently VZV-infected human TG. RNA-Seq read data presented in a linear format along the entire 125-kb VZV genome for TG specimens from donors 1 and 2 (Supplementary Table 1). Each track depicts either an unenriched or enriched poly-A-selected (pA) or rRNA-degraded (rRNA) VZV transcriptome. Blue and red tracks represent read data originating from the sense and antisense strand, respectively. y-axis values indicate read depth]. Previously described VZV ORFs (blue and red arrows) and the five VLT exons (light blue boxes) were scaled representatively. Paired-end read datasets were generated with read lengths of 2x76 bp.

Supplementary Figure 7 | The latent and lytic transcriptome of VZV. RNA-Seq read data for seven TG specimens and lytically VZV-infected ARPE-19 cells (Fig. 1), presented in a linear format along the entire 125-kb VZV genome. Each track depicts poly-A-selected, VZV-enriched transcriptomes. Blue and red tracks represent read data originating from the sense and antisense strand, respectively. Y-axis values indicate read depth. Unenriched tracks superimposed on ARPE-19 cells are shown in light blue (sense) or orange (antisense). Note that no VZV-mapping reads were obtained from unenriched sequence datasets generated for TG1 and TG2. Previously described VZV ORFs within this locus (blue and red arrows) and the five VLT exons (light blue boxes) are scaled representatively. Paired-end read datasets were generated with read lengths of 2x34 bp (ARPE-19) or 2x7 6bp (TG1 & TG2) or 2x151 bp (TG3 - TG7). VLT was consistently detected in all TGs. Background noise observed in TG1 likely reflects a combination of low sequencing depth and low VZV genome abundance (Supplementary Table 1).

Supplementary Figure 8 | The genomic locus encoding the VZV latency transcript. a, Schematic diagram showing the location and structure of the five VZV latency transcript (VLT) exons (blue blocks) and introns (black lines) within the genomic region 101,000-106,000 (coordinates refer to VZV reference strain Dumas; NC_001348.1) (Supplementary Table 3). **b,** The VLT mRNA sequence including the 5' untranslated region; start and stop codons are highlighted in red italic, while the cleavage factor I (CFI)-binding motifs are highlighted in green italic and the canonical polyadenylation signal site (AATAAA) is underlined. **c,** The fully translated VLT protein (pVLT), with the sequence of peptide used to produce rabbit polyclonal anti-pVLT antibody indicated in red.

Supplementary Figure 9 | Prevalence of VZV ORF63 RNA and VLT in human TG. **a**, Relative abundance of ORF63 RNA and VLT levels in 15 VZV nucleic acid positive (VZV^{POS}) human TG determined by RT-qPCR. VLT2-3 and VLT3-4 refer to primers/probes spanning the VLT exons 2→3 and 3→4 junctions (Supplementary Table 5). ORF63 RNA and VLT levels were paired in the same TG specimens. *** $p < 0.001$; Wilcoxon signed rank test. **b**, Correlation between relative ORF63 RNA and VLT levels, both normalized to cellular β -actin transcript levels. Spearman correlations are indicated. **c** and **d**, Correlation between relative ORF63 and VLT levels and VZV DNA load (**c**) and post-mortem interval (**d**) by qPCR in 15 VZV^{POS} human TG. Spearman correlations are indicated.

Supplementary Figure 10 | VLT-specific probe detects viral RNA, but not viral DNA in human TG by *in situ* hybridization. **a** and **b**, Analysis of negative control (bacterial gene dihydrodipicolinate reductase, DapB) and positive control [human gene RNA polymerase II polypeptide A (Polr2a) and ubiquitin C (UBC)] transcripts in human (**a**) latently VZV-infected adult TG and (**b**) VZV naïve fetal dorsal root ganglia by ISH. Magnification: 400X. **c**, Correlation between the percentages of ORF63 RNA- and VLT-positive neurons in latently VZV-infected human TG, determined by in situ hybridization (ISH). Spearman correlation is indicated. **d**, Analysis of ISH probe specificity using untreated, DNase-treated or RNase-treated consecutive sections of human TG. Magnification: 200X (Polr2a) and 400X (VLT). Arrowheads indicate the same neuron in adjacent TG sections. Representative images from two donors (n=2 sections/donor) are shown.

Supplementary Figure 11 | Comparison of VZV transcripts and HSV-1 LAT in human TG.

a, qPCR analysis of HSV-1 LAT, VZV ORF63 RNA and VLT levels in 13 latently HSV-1/VZV co-infected human TG (Supplementary Table 1). VLT2-3 and VLT3-4 indicate primer/probe sets spanning VLT exons 2→3 and 3→4 junctions (Supplementary Table 5). *** $p < 0.001$; Wilcoxon signed rank test. **b** and **c**, Analysis of HSV-1 LAT in ten latently HSV-1-infected human TG by ISH. **b**, Representative images of ISH analysis on human TG sections using probes specific for HSV-1 LAT, showing neuronal LAT staining in both the nucleus and cytoplasm (top panels) or solely nuclear (bottom panels). Magnification: 400X; inset: 400X and 3X digital zoom. **c**, Frequency of neurons expressing HSV-1 LAT (left panel), and frequency of neurons expressing LAT in both the nucleus and cytoplasm or only in the nucleus. Horizontal line and error bars indicate average $\pm$ SEM. * $p < 0.05$; paired Student's t-test.

Supplementary Figure 12 | Expression of VLT protein in transfected and lytically VZV-infected cells *in vitro*. **a**, Confocal microscopy image of untransfected ARPE-19 cells stained with antibodies to FLAG (red) and VLT protein (pVLT; green), as a negative control. **b**, Confocal microscopy images of uninfected ARPE-19 cells stained for proteins encoded by VZV gene VLT (pVLT; green) and ORF62 (IE62; red) (left panel), or pVLT (green) and VZV glycoprotein E (gE; red) (right panel) as a negative control. **c**, Confocal microscopy images of VZV pOka-infected and uninfected ARPE-19 cells stained for pVLT (green) and VZV IE62 (red) (left panel) or pVLT (green) and VZV gE (red) (right panel). Nuclei in **a-c** were stained with Hoechst 33342 (blue). Magnification: **(a)** 1000X and 2X digital zoom, **(b)** 1000X and **(c)** 200X. Bars=5 μ m **(a)**, 10 μ m **(b)** and 60 μ m **(c)**.

Supplementary Figure 13 | Co-localization of VZV ORF63 and VLT protein in human herpes zoster skin biopsies. Confocal microscopy image showing co-expression of protein encoded by VZV ORF63 (IE63; green) and VLT (pVLT; red) within the same cells of a human herpes zoster vesicle. Nuclei were counterstained with DAPI (blue). Magnification is indicated.

Supplementary Figure 14 | Validation of VLT protein expression in co-transfection experiments. Confocal microscopy image of untransfected ARPE-19 cells and of ARPE-19 cells transiently transfected with plasmids encoding FLAG-tagged VLT (VLT_{ATG}), mutated VLT lacking a start codon (VLT_{ATA}) or empty control plasmid, in combination with plasmids encoding ORF61, ORF62 and ORF63. Cells were stained using antibodies to FLAG (red) and VLT protein (pVLT; green); nuclei were stained with Hoechst (blue). Magnification: 600X. Bars=20 μ m.

Supplementary Tables

Supplementary Table 1. Clinical and virological parameters of human trigeminal ganglion donors used for RNA-sequencing and qPCR.

Donor ^a	Age (yrs)	Gender	Cause of death	Neurological Disease	PMI ^b (hr:mi n)	virus gec/10 ⁵ TG cells ^c		Virus transcript levels/100 ng RNA ^d			
						VZV	HSV-1	ORF6 3	VLT2 →3	VLT3 →4	LAT
1	93	Fem	Respiratory insufficiency	Alzheimer's Disease	5:20	30	30	0	1.0	1.9	8606
2	67	Fem	Heart failure	Alzheimer's Disease	6:45	249	26	3.2	26.8	54.7	11924
3	81	Male	Decompensatio cordis	Parkinson's Disease	5:15	164	23	1.5	54.4	79.7	2078
4	90	Fem	Sudden cardiac arrest	Alzheimer's Disease	4:45	91	7	11.9	412.4	489.0	5047
5	67	Male	Euthanasia	Alzheimer's Disease	8:00	28	29	0.5	4.3	9.0	8869
6	89	Male	Sepsis	Alzheimer's Disease	4:56	188	0 ^e	8.2	131.9	188.7	1004
7	73	Fem	Heart failure	Parkinson's Disease	4:40	99	13	2.4	48.4	114.7	6906
8	83	Fem	Urosepsis and aspiration pneumonia	Other Neurological Disease	5:20	43	553	0	0.3	0.6	10739
9	71	Male	Cardiovascular accident	Parkinson's Disease	5:05	84	5	0	2.3	4.8	1161
10	71	Fem	Dehydration and cachexia	Alzheimer's Disease	4:15	66	0	0.4	12.1	17.4	0
11	69	Male	Dehydration and cachexia	Alzheimer's Disease	6:05	84	119	0	5.2	10.0	3094
12	47	Fem	Euthanasia	Non-demented control	6:05	494	0	0.3	3.6	3.3	0
13	66	Male	Uremia/cachexia	Alzheimer's Disease	7:00	26	29	0	0	0	8205
14	89	Fem	Euthanasia	Non-demented control	4:45	0 ^e	0	0	0.9	1.2	8648
15	80	Male	Dehydration and cachexia	Other Neurological Disease	6:35	0 ^e	0	0.4	2.0	1.3	2699
16	69	Fem	Euthanasia	Other Neurological Disease	4:30	0	42	0	0	0	6905
17	95	Fem	Alzheimer's disease and dehydration	Alzheimer's Disease	5:30	0	1	0	0	0	24
18	83	Male	Aspiration pneumonia	Multiple sclerosis	7:50	0	10	0	0	0	1

^a Donors 1 – 7 were used for RNA-sequencing; donors 1, 3 and 5 were used for miRNA-sequencing; donors 1 – 18 were used for quantitative real-time PCR (qPCR)

^b PMI: post-mortem interval

^c Viral DNA load in genome equivalent copies (gec) per 10⁵ trigeminal ganglia (TG) cells, as determined by virus-specific and single copy gene hydroxymethylbilane synthase (HMBS)-specific real-time PCR on DNA isolated from about one-fifth part of each TG specimen.

^d Viral transcript copies per 100 ng total RNA isolated from about four-fifth part of each TG specimen. LAT, HSV-1 latency-associated transcript; ORF63, VZV open reading frame 63; VLT2→3 and VLT3→4, VZV latency transcript (VLT) fragment detected by reversed transcribed real-time PCR using specific primer/probe-combinations.

^e Individual TG were cut so that approximately one-fifth TG was used for DNA isolation and four-fifth was used for RNA isolation. Occasionally, discrepancies between viral DNA and cDNA qPCRs were observed, most likely due to unequal distribution of HSV-1 among TG neurons and low number of neurons harboring latent VZV. TG positive for either viral DNA or RNA were considered positive for the respective virus, while TG in which no viral nucleic acids could be detected were considered negative for the virus.

Supplementary Table 2. RNA-sequencing metrics.

RNA source ^a	Protocol ^b	Enrichment ^c	Read length (bp)	Total read pairs	Varicella-zoster virus (VZV)			Herpes simplex virus type 1 (HSV-1)				
					Mapping read pairs	%	Diversity index ^d	De-duplicated read pairs	Mapping read pairs	%	Diversity index ^d	De-duplicated read pairs
TG #1	polyA	VZV & HSV-1	2x75	49,173,713	7,180	0.01	0.975	181	20,937,718	42.58	0.998	46,831
	polyA	None	2x75	99,471,313	0	0.00	0.000	0	1,754	0.00	0.131	1,524
	rRNA	VZV & HSV-1	2x75	50,935,304	5,939	0.01	0.997	18	27,548,446	54.09	0.997	81,254
	rRNA	None	2x75	50,215,904	0	0.00	0.000	0	843	0.00	0.069	785
TG #2	polyA	VZV & HSV-1	2x75	48,348,467	49,116	0.10	0.998	108	24,815,982	51.33	0.998	56,477
	polyA	None	2x75	90,146,278	0	0.00	0.000	0	1149	0.00	0.128	1,002
	rRNA	VZV & HSV-1	2x75	46,504,366	31,910	0.07	0.998	53	27,744,406	59.66	0.998	55,857
	rRNA	None	2x75	65,995,396	0	0.00	0.000	0	1071	0.00	0.105	959
TG #3	polyA	VZV & HSV-1	2x150	92,777,528	408,427	0.44	0.998	829	7,837,812	8.45	0.997	23,058
TG #4	polyA	VZV & HSV-1	2x150	87,656,593	894,765	1.02	0.999	983	11,540,872	13.17	0.998	22,174
TG #5	polyA	VZV & HSV-1	2x150	72,643,442	53,030	0.07	0.992	414	16,463,232	22.66	0.992	81,607
TG #6	polyA	VZV & HSV-1	2x150	107,702,307	480,559	0.45	0.997	1,319	28,815,264	26.75	0.995	130,424
TG #7	polyA	VZV & HSV-1	2x150	91,143,646	212,995	0.23	0.998	351	10,423,148	11.44	0.996	36,490
ARPE-19/HSV-1 #1	polyA	HSV-1	2x34	20,000,000 ^e (79,677,197)	275	0.00	0.404	164	19,543,817	97.72	0.789	4,117,726
	polyA	None	2x34	20,000,000 ^e (32,199,707)	86	0.00	0.291	61	13,192,165	65.96	0.806	2,564,304
ARPE-19/HSV-1 #2	rRNA	HSV-1	2x34	20,000,000 ^e (76,360,350)	243	0.00	0.325	164	19,487,687	97.44	0.795	3,987,408
	rRNA	None	2x34	20,000,000 ^e (26,101,860)	205	0.00	0.063	192	15,905,450	79.53	0.836	2,601,054
ARPE-19/VZV #1	polyA	VZV	2x34	20,000,000 ^e (62,922,757)	18917428	94.59	0.810	3,598,314	419	0.00	0.468	223
	polyA	None	2x34	20,000,000 ^e (44,024,427)	3,759,823	18.80	0.691	1,162,827	57	0.00	0.070	53

^a RNA was isolated from human trigeminal ganglia (TG) or human retina pigmented epithelial line ARPE-19 cells lytically infected with HSV-1 (ARPE-19/HSV-1) or VZV (ARPE-19/VZV). TG coding refers to donor ID presented in Supplementary table 1.

^b Protocol refers to total RNA selected for polyadenylated RNA (polyA) or depleted for ribosomal RNA (rRNA).

^c RNA libraries were enriched for HSV-1- and/or VZV-specific sequences or left untreated (none).

^d Diversity index represents the complexity of the library (in other words, the level of read duplicates that can be attributed to PCR is calculated using PicardTools RemoveDuplicates).

^e Sequence datasets were subsampled to 20,000,000 read-pairs due to facilitate mapping of VZV and HSV-1 reads. Total numbers of read-pairs are showing in brackets.

Supplementary table 3. Location and nucleotide sequence of the exons and introns of varicella-zoster virus latency transcript.

	Start ^a	End	Length ^b	Sequences ^c
Exon 1	102,421	102,483	63	ACTATCCAGT TGGCATTTTA AACGGGTCCG GCTGCCTAAA CCGAAACAC CGTTGCCTTT ACT
Intron 1	102,484	102,853	370	GT AAGTACAA AACTAAATT TATATTTGCG GTTAGACTGT TATGTTTATT GTATTTGC AG
Exon 2	102,854	102,982	129	AGCAGG ATG C CCCGGTTACT CCGAGACCGG CCAACCCCTTA CGACCAATAG CAACACTCAG
Intron 2	102,983	103,827	845	GT ATTTTTAA AATGCACGTT TAATGATCAT ATGGTTCGTG GGTCTTGATT AATCCCAC AG
Exon 3	103,828	103,923	96	ATACTGGACG ATCAGCGTAG TCCTGCCCCC ACACCACCGG GGTCGCCGAT CGAACAGCAG
Intron 3	103,924	104,293	370	GT TGGTCTTT AAAAAATACC TTCCGTAATA GTAACCTGTA TCACCTACGA TCTTATGC AG
Exon 4	104,294	104,432	139	GATGGATTGC ACTGGACACC GGCAGAGAGG TCGGAAACGG TGCTCATGCA TATGGTGCAG
Intron 4	104,433	104,768	336	GT ATTATCCG AAGCGTCGGA GGTGCCGCTA AGTGACATTT TAGATTCTGT CTTTATTT AG
Exon 5	104,769	104,837	69	ATAAGAGCG ATACGAAGAC ATTCTCCAC CCCCCTGTAA TACCCGTAAA TAA AGGTAAG TCCACAAAC

^a Coordinates of VLT exons and introns with respect to VZV reference strain Dumas (NCBI Reference Sequence: NC_001348.1).

^b Sequence length in base pairs.

^c **GT**: splice donor site; **AG**: splice acceptor site; **ATG**: start codon; **TAA**: stop codon.

Supplementary Table 4. Single Nucleotide Polymorphisms (SNPs) across the VLT locus^a

Genome position ^b	Reference base ^b	Variant base	ORF	Type of mutation	Codon position	Mutation	Number of genomes ^c	Note
102002	T	C	n.a.	non-coding	.	.	1 (0)	
102232	C	A	n.a.	non-coding	.	.	1 (0)	
102268	T	C	n.a.	non-coding	.	.	1 (0)	
102309	C	A	n.a.	non-coding	.	.	21 (6)	
102351	A	C	n.a.	non-coding	.	.	19 (6)	
102401	G	A	n.a.	non-coding	.	.	1 (0)	VLT exon 1
102403	A	G	n.a.	non-coding	.	.	1 (0)	VLT exon 1
102403	A	C	n.a.	non-coding	.	.	8 (0)	VLT exon 1
102458	A	G	n.a.	non-coding	.	.	21 (6)	VLT exon 1
102510	T	C	n.a.	non-coding	.	.	2 (0)	VLT intron
102575	A	G	n.a.	non-coding	.	.	2 (0)	VLT intron
102596	C	A	n.a.	non-coding	.	.	1 (0)	VLT intron
102601	T	G	n.a.	non-coding	.	.	19 (6)	VLT intron
102617	C	T	n.a.	non-coding	.	.	3 (0)	VLT intron
102684	A	T	n.a.	non-coding	.	.	1 (0)	VLT intron
102738	T	C	n.a.	non-coding	.	.	2 (0)	VLT intron
102850	G	A	n.a.	non-coding	.	.	1 (1)	VLT intron
102908	C	T	VLT	non-synonymous	1	R17T	1 (0)	VLT exon 2
102970	A	G	VLT	synonymous	3	Q37	2 (0)	VLT exon 2
102977	C	T	VLT	non-synonymous	1	H40T	1 (1)	VLT exon 2
103043	T	C	n.a.	non-coding	.	.	20 (6)	VLT intron
103169	A	G	ORF61	synonymous	3	S439	1 (2)	VLT intron
103205	A	G	ORF61	synonymous	3	P427	1 (0)	VLT intron
103261	A	G	ORF61	non-synonymous	1	T409A	1 (0)	VLT intron
103295	C	T	ORF61	synonymous	3	G397	8 (0)	VLT intron
103322	T	C	ORF61	synonymous	3	G388	1 (0)	VLT intron
103613	G	T	ORF61	synonymous	3	A291	2 (0)	VLT intron
103754	A	G	ORF61	synonymous	3	G244	1 (0)	VLT intron
103778	A	G	ORF61	synonymous	3	R246	2 (0)	VLT intron
103799	C	T	ORF61	synonymous	3	T229	1 (0)	VLT intron
103805	A	G	ORF61	synonymous	3	P227	1 (0)	VLT intron
103955	A	C	ORF61	synonymous	3	S177	1 (0)	VLT intron
104047	G	A	ORF61	non-synonymous	1	A147T	1 (0)	VLT intron

104120	A	G	ORF61	<i>synonymous</i>	3	T122	1 (0)	VLT intron
104135	C	T	ORF61	<i>synonymous</i>	3	S117	1 (0)	VLT intron
104156	C	T	ORF61	<i>synonymous</i>	3	S110	1 (0)	VLT intron
104275	G	A	ORF61	<i>non-synonymous</i>	1	D71N	1 (0)	VLT intron
104403	A	G	VLT	non-synonymous	2	D110G	1 (0)	VLT exon 4
	T	C	ORF61	<i>synonymous</i>	3	D28	1 (0)	VLT intron
104406	G	A	VLT	non-synonymous	2	R111E	7 (0)	VLT exon 4
	C	T	ORF61	<i>synonymous</i>	3	S27	7 (0)	VLT intron
104472	T	C	ORF61	<i>non-synonymous</i>	2	L5S	1 (0)	VLT intron
104477	C	T	ORF61	<i>synonymous</i>	3	T3	1 (0)	VLT intron
104684	A	C	n.a.	non-coding	.	.	1 (0)	
104723	G	T	n.a.	non-coding	.	.	1 (1)	
104737	T	G	n.a.	non-coding	.	.	1 (0)	
104738	A	C	n.a.	non-coding	.	.	2 (0)	
104749	T	C	n.a.	non-coding	.	.	1 (0)	
104865	G	A	n.a.	non-coding	.	.	1 (0)	
104877	T	G	n.a.	non-coding	.	.	1 (0)	
104882	C	A	n.a.	non-coding	.	.	11 (0)	
104898	A	G	n.a.	non-coding	.	.	84 (6)	
104913	G	A	n.a.	non-coding	.	.	1 (0)	
104933	G	A	n.a.	non-coding	.	.	4 (0)	
104939	C	-	n.a.	non-coding	.	.	1 (0)	

^a SNPs within the coding region of VLT are shown in bold and within ORF61 are shown using italics.

^b Reference bases and genome co-ordinates correspond to VZV reference strain Dumas NC_001348.1

^c Data originate from a multiple sequence alignment of VZV wildtype (n = 88) and vaccine / vaccine rash (n = 38) strains obtained from Genbank in August 2017. The numbers of wildtype and (vaccine rash) genomes carrying the SNP are reported.

Supplementary Table 5. Primers and probes.

Name ^a	Target ^b	Sequence (5' → 3')	Modifications ^c	
			5'	3'
VLT2-3_Probe	VZV VLT splice junction exons 2→3	GCA-ACA-CTC-AGA-TAC-TGG-ACG-ATC	6-FAM	BHQ1
VLT2-3_Fw	VZV VLT exon 2	GAC-TTA-CCA-GGG-GGC-AGT-AT	none	none
VLT2-3_Rv	VZV VLT exon 3	CGG-TGG-TGT-ATG-GCT-CGA-TT	none	none
VLT3-4_Probe	VZV VLT splice junction exons 3→4	GAT-CGA-ACA-GCA-GAT-GGA-TTG-CAC	6-FAM	BHQ1
VLT3-4_Fw	VZV VLT exon 3	AAT-CGA-GCC-ATA-CAC-CAC-CG	none	none
VLT3-4_Rv	VZV VLT exon 4	TGT-ATT-CGG-GCA-TGG-ACC-TC	none	none
ORF62_Probe	VZV ORF62	TGC-AAC-CCG-GGC-GTC-CG	6-FAM	BHQ1
ORF62_Fw	VZV ORF62	CCT-TGG-AAA-CCA-CAT-GAT-CGT	none	none
ORF62_Rv	VZV ORF62	AGC-AGA-AGC-CTC-CTC-GAC-AA	none	none
ORF63_Probe	VZV ORF63	TGT-CCC-ATC-GAC-CCC-CTC-GG	6-FAM	BHQ1
ORF63_Fw	VZV ORF63	GCT-TAC-GCG-CTA-CTT-TAA-TGG-AA	none	none
ORF63_Rv	VZV ORF63	GCC-TCA-ATG-AAC-CCG-TCT-TC	none	none
HMBS_probe	Human hydroxymethylbilane synthase	TGG-AAG-CTA-ATG-GGA-AGC-CCA-GTA-CC	6-FAM	TAMRA
HMBS_Fw	Human hydroxymethylbilane synthase	GCC-TGC-AGT-TTG-AAA-TCA-GTG	none	none
HMBS_Rv	Human hydroxymethylbilane synthase	CGG-GAC-GGG-CTT-TAG-CTA	none	none
ORF29F2381	VZV ORF29	GCC-TTG-CAA-GTG-CGT-ACC	none	none
ORF29R2440	VZV ORF29	CTA-GGG-CCC-CGT-GTA-ACA-TA	none	none
VLT exon1F	VZV VLT exon 1	GGC-ATT-TTA-AAC-GGG-TCC-GG	none	none
VLT exon2R-1	VZV VLT exon 2	CCC-TGG-TAA-GTC-CGT-ACA-CG	none	none

VLTup22ecoF	VZV VLT	ACC-GAA-TTC-CAC-CGT-TGC-CTT-TAC-TAG-CAG	none	none
VLT-FLAGxhoR	VZV VLT	ACC-CTC-GAG-TTA-CTT-GTC-GTC-ATC-GTC-TTT-GTA-GTC-TTT-ACG-GGT-ATT-ACA-GGG	none	none
VLT-G3A	VZV VLT	TAT-TTG-CAG-AGC-AGG-ATA-CCC-CGG-TTA-CTC-CGA	none	none
ORF61up20ecoF	VZV ORF61	ACC-GAA-TTC-GAA-TAC-AGC-CAG-TTG-TTA-CC	none	none
ORF61salR	VZV ORF61	ACC-GTC-GAC-CTA-GGA-CTT-CTT-CAT-CTT-GTT-TGG	none	none
ORF63up20exoF	VZV ORF63	ACC-GAA-TTC-GTT-ACT-ACG-GCC-CCA-AGG	none	none
ORF63xhoR	VZV ORF63	ACC-CTC-GAG-CTA-CAC-GC-CAT-GG	none	none
VLTexon2F	VZV VLT exon 2	CAG-GAT-GCC-CCG-GTT-ACT-C	none	none
VLTexon2R-2	VZV VLT exon 2	GCT-ATT-GGT-CGT-AAG-GGT-TGG	none	none
HHV1_LAT_Fw	HSV-1 LAT 2.0kb intron	CCC-ACG-TAC-TCC-AAG-AAG-GC	none	none
HHV1_LAT_Rv	HSV-1 LAT 2.0kb intron	AGA-CCC-AAG-CAT-AGA-GAG-CCA-G	none	none
HHV1_LAT_Probe	HSV-1 LAT 2.0kb intron	CCC-ACC-CCG-CCT-GTG-TTT-TTG-TG	6-FAM	BHQ1
NheI_VLT_F	VZV VLT	GCA-GCT-AGC-ATG-CCC-CGG-TTA-CTC-CG	none	none
VLT_R_BamHI	VZV VLT	CGT-GGA-TCC-TTA-TTT-ACG-GGT-ATT-ACA-GGG-G	none	none
ORF62F2016	VZV ORF62	TCC-ACC-GGA-TGA-TCG-TTT-AC	none	none
ORF62R2083	VZV ORF62	GGA-GGC-TTC-TGC-TCT-CGA-C	none	none
VLT_E-1A_Probe	VZV VLT splice junction exon A → exon1	CAA-AGC-ATC-GCA-CTA-TCC-AGT-TGG	6-FAM	BHQ1
VLT_E-1A_Fw	VZV VLT exon A	CCA-TAC-ACC-GGA-AAG-GGC-AT	none	none
VLT_E-1B_Probe	VZV VLT splice junction exon B → exon1	GGA-AGC-ATG-GAC-AAC-TAT-CCA-GTT-G	6-FAM	BHQ1
VLT_E-1B_Fw	VZV VLT exon B	TGT-TTT-CCC-TTC-ACT-ACG-ACG-T	none	none
VLT_E-1C_Probe	VZV VLT splice junction exon C → exon1	AGA-TTG-ATT-TGC-GAC-TAT-CCA-GTT-GG	6-FAM	BHQ1
VLT_E-1C_Fw	VZV VLT exon C	CCC-AAC-GGC-CAT-TAT-CCC-TT	none	none
VLT_E1_Rv	VZV VLT exon 1	AAA-GGC-AAC-GGT-GTT-TTC-GG	none	none
VLT2	VZV VLT exon 2	GCT-ATT-GGT-CGT-AAG-GGT-TGG	none	none
RACEout_Fw	5'RACE Adapter	GCT-GAT-GGC-GAT-GAA-TGA-ACA-CTG	none	none
RACEin_Fw	5'RACE Adapter	CGC-GGA-TCC-GAA-CAC-TGC-GTT-TGC-TGG-CTT-TGA-TG	none	none
Universal Primer A Mix	RACE Adapter (Mixture of Long and Short)	Long: CTA-ATA-CGA-CTC-ACT-ATA-GGG-CAA-GCA-GTG-GTA-TCA-ACG-CAG-AGT Short: CTA-TAG-GGC-AAG-CAG-TGG-TAT-CAA-CGC-AGA-GT	none	none
ORF61R626AS	Anti-sense to VZV ORF61 (VLT exon 3)	CCG-GGG-GGC-AGG-ACT-ACC-GTG-AT	none	none
ORF61F131AS	Anti-sense to VZV ORF61 (VLT exon 4)	GAC-GCT-GGT-GGA-GGT-CCA-TGC-CCG-AA	none	none
pOka104778R	VZV VLT exon 5	ACC-CTC-GAG-TAC-GGG-TAT-TAC-AGG-G	none	none
M13_Fw	pCR4-TOPO TA vector	TGT-AAA-ACG-ACG-GCC-AGT	none	none
M13_Rv	pCR4-TOPO TA vector	CAG-GAA-ACA-GCT-ATG-ACC	none	none

^a VLT, varicella-zoster virus (VZV) latency transcript; ORF, open reading frame; Rv, reverse; Fw, forward.

^b 5'RACE Adapter sequences from FirstChoice™ RLM-RACE Kit (Ambion).

^c 6-FAM, 6-carboxyfluorescein; BHQ1, black hole quencher 1; TAMRA, tetramethylrhodamine.

Materials and Methods

Human clinical specimens

Human trigeminal ganglia (TG), obtained at $6:01 \text{ h} \pm 1:47 \text{ hr}$ (average $\pm$ SD) after death, were provided by the Netherlands Brain Bank (Amsterdam, the Netherlands) (Supplementary Table 1). All individuals provided prior written informed consent for brain autopsy and the use of material and clinical information for research purposes. All study procedures were performed in compliance with relevant Dutch laws and institutional guidelines, approved by the local ethical committee (VU University Medical Center, Amsterdam, project number 2009/148) and was performed in accordance with the ethical standards of the Declaration of Helsinki. Majority of TG donors had a neurologic disease history affecting the central nervous system (mainly Alzheimer's and Parkinson's disease) and cause of death was not related to herpesvirus infections. TG biopsies were either formalin-fixed and paraffin-embedded (FFPE) or snap-frozen in liquid nitrogen and stored at -80°C . Human fetal DRG were obtained from the Academic Medical Centre Amsterdam (the Netherlands) according to relevant Dutch laws and approved by the institutional ethical committee (Erasmus MC, Rotterdam, MEC-2017-009). FFPE punch biopsies of one healthy control subject and five herpes zoster skin lesions were obtained for diagnostic purposes. Zoster biopsies were confirmed VZV DNA positive by virus-specific real-time PCR (qPCR). According to the institutional "Opt-Out" system (Erasmus MC, Rotterdam, the Netherlands), which is defined by the National "Code of Good Conduct" [Dutch: Code Goed Gebruik, May 2011], the surplus human herpes zoster FFPE tissues were available for the current study.

Cells and viruses

Human retinal pigmented epithelium ARPE-19 cells [American Type Culture Collection (ATCC) CRL-2302] were maintained in 1:1 DMEM (Lonza or Nissui)-Ham's F12 (Lonza or Sigma-Aldrich) medium supplemented with 8% heat-inactivated fetal bovine serum (FBS; Lonza or Sigma-Aldrich) and 0.6 mg/mL L-sodium glutamate (Lonza or Nacalai). The human MeWo melanoma cell was maintained in DMEM supplemented with 8% FBS and 0.6 mg/mL L-sodium glutamate. Culture of VZV pOka strain and isolation of cell-free virus have been described previously³¹. Low passage clinical isolates VZV EMC-1 and HSV-1 strain F (ATCC VR-733) were cultured on ARPE-19 cells as described³²⁻³⁴. All cell cultures and virus infections were performed in a humidified CO₂ incubator at 37°C.

Nucleic acid extraction from human TG

Approximately one-fifth of snap-frozen human TG was mechanically dispersed and used for DNA isolation, while four-fifths of the same specimen was used for RNA isolation. DNA extraction was performed using the QIAamp DNA kit (Qiagen) according to the manufacturer's instructions. For RNA isolation, samples were homogenized in TRIzol (Invitrogen), mixed vigorously with 200 µL chloroform and centrifuged for 15 min at 12,000xg at 4°C. RNA was isolated from the aqueous phase using the RNeasy Mini Kit, including on-column DNase I treatment (Qiagen). DNA and RNA concentration and integrity were analysed using a Qubit Fluorometer (ThermoFisher).

RNA extraction from lytic VZV and HSV-1 infections

ARPE-19 cells were infected with VZV strain EMC-1 by co-cultivation VZV-infected or uninfected cells at a 1:8 cell ratio and harvested in 1 mL TRIzol at 72 hrs post-infection (hpi). Alternatively, semi-confluent ARPE-19 cell layers (75 cm² flask) were infected with HSV-1 strain F at a multiplicity of infection (MOI) of 1 and harvested in 1 mL TRIzol at 24 hpi. RNA isolated as

described above was subjected to additional DNase treatment using the TURBO DNA-free kit according to the manufacturer's instructions (Ambion).

RNASeq library preparation and sequencing

Four micrograms of total RNA was used as input for the SureSelectXT RNA Target Enrichment protocol (Agilent Technologies G9691 version D0). Here, each sample was either enriched for polyadenylated mRNA (captured by oligo-dT beads, as described by the SureSelect XT protocol) or underwent rRNA-depletion using a NEBNext® rRNA Depletion Kit [Human/Mouse/Rat] (New England Biolabs) according to manufacturer's instructions. Subsequent to either procedure, captured/remaining RNAs were transcribed to produce cDNA. Fragmentation, cDNA second strand synthesis, end repair, A-tailing and adapter ligation were performed as described in the enrichment protocol. Hybridisation was performed using a modified strategy^{20,21} that incorporated custom-designed SureSelect RNA bait sets for both VZV and HSV-1 in the same reaction at reduced concentration (1:10). Bait sets for VZV and HSV-1 were designed at 12x tiling (i.e. each base position in the genome was covered by 12 distinct 120-mer bait sequences) using custom in-house scripts and are available from the authors upon request. Hybridisation for 24 hrs at 65°C was followed by post-capture washing and optimised PCR-based library indexing (12 cycles for RNA obtained from lytically-infected cultures, 18 cycles for RNA obtained from TGs). Libraries generated from VZV- and HSV-1-infected ARPE-19 cells were multiplexed and sequenced using a 75 cycle V2 high-output kit. Subsequently, three TG were multiplexed sequenced using a 150 cycle V2 mid-output kit followed by a further four TG multiplexed and sequenced using a 300 cycle V2 high-output kit. The decision to use increasing read lengths was informed by the initial discovery of VLT and the desire to better characterise intron splicing.

Transcriptome mapping and *de novo* transcript reconstruction

Sequence run data were de-multiplexed using bcl2fastq2 v2.17 under stringent conditions (--barcode mismatches 0) and yielded between ~ 31,000,000 – 107,700,000 paired-end reads per sample. Individual sequence datasets were trimmed using TrimGalore software (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to remove low quality 3' ends and mapped to the human genome (hg19) using BMap software (<http://sourceforge.net/projects/bbmap/>) with default parameters. Unmapped read pairs were subsequently aligned against VZV Dumas (NC_001348) and HSV-1 strain 17 (NC_001806) reference genomes deposited at Genbank using BMap allowing for properly paired reads only to be carried forward in the analysis. Extremely high duplication levels (>0.99) were observed in all enriched libraries generated from TG RNA, an expected feature of enrichment strategies against ultra-low abundance transcripts. Note however that we are not stating that VLT is a low-abundance transcript within a single cell but rather that VZV latently-infected cells are relatively scarce, thus diluting the apparent expression level of VLT. To mitigate this, duplicate reads were removed using Picard Tools MarkDuplicates software (<http://broadinstitute.github.io/picard>). Resulting assemblies were visualised using a combination of Circos³⁵, Artemis³⁶, Tablet³⁷, SeqMonk (<http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/>) software and custom R scripts making use of the Rsamtools and Gviz software packages.

To confirm that enrichment for viral nucleic acids did not bias relative levels of viral gene transcription, transcripts per million (TPM) counts were generated using featurecounts (subread package^{38,39}) and visualised using scatter plots. High correlation (R^2 0.9252 - 0.9678) between enriched and unenriched transcriptomes were observed for both HSV-1 (n=2 biological replicates) and VZV (n=1), as shown in Supplementary Figure S1.

For *de novo* transcript reconstruction, VZV-specific mapping read pairs for each TG were extracted from BAM files and converted to raw fastq format for input into Trinity⁴⁰. Trinity enables transcript reconstruction and, while limited in this case by the scarcity of VZV reads,

was able to merge overlapping reads to produce transcript isoforms that, when mapped to the VZV reference genome using BBmap, spanned the four major introns observed in the VZV latency transcript.

MicroRNA sequencing (miRNASeq) and qPCR profiling

miRNASeq libraries were prepared from 1 µg of total RNA, isolated from human TG and lytically VZV- and HSV-1-infected ARPE-19 cells, using the NEBNext® small RNA Library Prep Set for Illumina® according to manufacturer's instructions. Libraries underwent 75bp single-end sequencing using an Illumina NextSeq prior to demultiplexing (as outlined above). Sequence reads were adaptor-trimmed using TrimGalore and size selected using BBduk (provided with BBmap) so that only sequence reads between 17-26 bases in length were retained. These were mapped against VZV strain Dumas and the HSV-1 strain 17 reference genomes as well as miRDB using ShortStack (--dicernin 18 --mincov 1 --mismatches 2 --foldsize 200). No putative VZV miRNAs could be detected in either latently infected TGs or lytically infected ARPE-19 cells. By contrast, canonical HSV-1 miRNAs could be detected in both latently infected TGs and lytically infected ARPE-19 cells at high abundance.

cDNA synthesis and qPCR

cDNA synthesis was performed as described⁸ using 2.0 – 11.7 µg [6.7 µg ± 0.64 (average ± SEM)] of TG-derived total RNA or 5 µg of cell-culture derived DNase-free RNA and Superscript III reverse transcriptase (Invitrogen) with oligo(dT)12-18 primers (Invitrogen). Taqman qPCR was performed in triplicate on DNA and cDNA using Taqman 2X PCR Universal Master Mix (Applied Biosystems) with primer/probe pairs specific for VZV ORF62, ORF63, and the VLT exon 2→3, 3→4, A→1, B→1 and C→1 junctions and HSV-1 DNA⁴¹ and LAT, (all from Eurogentec), β-actin (Applied Biosystems) and the human single copy gene hydroxymethylbilane synthase (HMBS) (Supplementary Table 5). Commercially quantified VZV

and HSV-1 DNA stocks (Advanced Biotechnologies) and plasmids encoding VZV DNA amplicons (ORF63 and VLT) were used to standardize qPCR reactions and used as positive control in each qPCR. RT-qPCR data were presented as absolute transcript copy number per 100 ng RNA (Fig. 2d and Supplementary figs. 9a and 11a), relative transcript levels defined as $2^{-(\text{Ct-value VZV gene} - \text{Ct-value } \beta\text{-actin})}$ (Figs. 2c and 2e, Supplementary figs. 9b-d), and fold change in gene expression using the $2^{-\Delta\Delta\text{Ct}}$ method⁴² in which transcript levels were normalized to β -actin and a reference sample (Figs. 3c and 4a).

Sequence analysis of lytic VLT isoforms

5'RACE and 3'RACE were performed using the SMARTer™ RACE cDNA Amplification Kit (Clontech) according to the manufacturer's instructions using total RNA extracted from VZV pOka infected MeWo cells. PCR was performed using KOD-Plus-Ver.2 DNA Polymerase (Toyobo Life Science) templated with 5'RACE ready cDNA using Universal Primer A Mix and ORF61R626AS or pOka104778R, or 3'RACE ready cDNA using Universal Primer A Mix and ORF61R626AS (Supplementary Table 5). Alternatively, 5'Rapid amplification of cDNA ends (RACE) was performed using the FirstChoice™ RLM-RACE Kit (Ambion) according to the manufacturer's instructions, using 10 µg of total RNA obtained from VZV EMC-1 infected ARPE-19 cells. Nested PCR was performed using Pfu Ultra II Fusion HS DNA Polymerase (Stratagene) and 40 cycles of first round amplification using 5'RACEout_Fw – VLT2-3_Rv primers, followed by 40 cycles of second round amplification using 5'RACEinn_Fw – VLT2_Rv primers (Supplementary Table 5). PCR products were cloned into the pCR™4-TOPO® TA vector (Thermo Fisher Scientific) after addition of 3'A overhang using AmpliTaq Gold DNA polymerase (Thermo Fisher Scientific) or Takara Ex Taq® (Takara Bio) and used to transform One Shot® TOP10 competent *E. coli*. Plasmid DNA was extracted using the QIAprep Spin Miniprep Kit (Qiagen), amplified by PCR using M13Fw and M13Rv primers (Supplementary Table 5) and Pfu Ultra II Fusion HS DNA Polymerase (Stratagene). Plasmid DNAs or purified

PCR products were sequenced on the ABI Prism 3130 XL Genetic Analyzer using the BigDye v3.1 Cycle Sequencing Kit (both Applied Biosciences) and M13Fw and M13Rv primers. Resultant FASTA sequences were aligned the VZV reference genome Dumas using BBmap, as outlined above. Resultant assemblies were inspected alongside RNASeq data using IGV⁴³.

In situ hybridisation

To select for VZV and HSV-1 DNA positive TG tissue areas, DNA was isolated from three consecutive 5 µm FFPE tissue sections using the QIAamp DNA FFPE Tissue Kit and analysed by the respective virus-specific qPCR assays. Subsequently, viral DNA^{POS} FFPE TG specimens, human fetal DRG (negative control) and human zoster skin biopsies were analysed by *in situ* hybridization (ISH) using the RNAScope 2.0 red kit (Advanced Cell Diagnostics) according to the manufacturer's instructions. In brief, deparaffinised 5 µm tissue sections were incubated with probes designed to cover VZV ORF63 and VLT exons 2 to 5. The probes for the human transcript POLR2A and ubiquitin C (UBC) were used as positive controls and probes specific for the bacterial transcript DAPB were used as negative controls. All probes were designed and produced by Advanced Cell Diagnostics. FastRed was used as substrate to visualize the ISH signal and stained slides were counterstained with haematoxylin and mounted in Ecomount (Biocare Medical). In some experiments, TG sections were incubated with DNase I (Qiagen) or RNase [Ribonuclease A (25µg/mL) + T1 (25 units/mL; both Thermo Fisher Scientific) diluted in 1xTBS-t], after pre-treatment step #3 for 1 hr at 40°C. To determine the ratio of VZV and HSV-1 transcript expressing TG neurons, slides were scanned using the Nanozoomer 2.0 HT (Hamamatsu) and scored in Adobe Photoshop CS6 (Adobe). Twelve TG from distinct donors were analysed for VZV ORF63 and VLT and 10 TG for HSV-1 LAT, with on average 664 neurons/section (range: 420-1561) and 1-2 sections per TG. Two herpes zoster skin biopsies from distinct donors were analysed with 2-3 sections per donor for each staining.

Determination of kinetic class of VZV transcripts

ARPE-19 cells (2×10^5 cells) were infected with pOka VZV cell-free virus (10^3 plaque forming units) with and without phosphonoformic acid (PFA; 200 $\mu\text{g/mL}$) for 24 hrs at 37°C. Total RNA was isolated from cells using NucleoSpin RNA in combination with the NucleoSpin RNA/DNA buffer set (Macherey-Nagel) according to the manufacturer's instructions. Binding DNA was first eliminated from the column in 100 μL DNA elution buffer, the column was treated with recombinant DNase I (5 units/100 μL ; Roche Diagnostics) for 1 hr at 37°C and finally RNA was eluted in 60 μL nuclease free water. cDNA was synthesized with 10.4 μL of total RNA and anchored oligo(dT)₁₈ primer in a 20 μL reaction using the Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). qPCR following a dissociation curve analysis was performed as described previously¹⁸ using SYBR Select Master Mix in a StepOnePlus Real-time PCR system (Thermo Fisher Scientific). The primer sets for β -actin, and VZV ORF61 and ORF49 genes were described previously¹⁸ and primers for VZV ORF29 (ORF29F2381 and ORF29R2440) and VLT (VLT exon1F and VLT exon2R) are presented in Supplementary Table 5.

Plasmid construction

The VLT coding sequence (102,468 - 104,818, excluding introns indicated in Supplementary Table 3), ORF61 and ORF63 coding sequences were amplified by PCR of cDNA prepared from pOka-infected MeWo cells showing >80% cytopathic effect using the primer sets VLTup22ecoF and VLT-FLAGxhoR, ORF61up20ecoF and ORF61SalR, or ORF63up20ecoF and ORF63xhoR, respectively (Supplementary Table 5). Products were digested with EcoRI and XhoI (VLT and ORF63), or EcoRI and SalI (ORF61), restriction enzymes and subsequently cloned into pCAGGS-MCS-puro (CAG.Empty) via EcoRI and XhoI sites. The resulting VLT, ORF61 and ORF63 expressing plasmids were named as follows: CAG.VLT-FLAG, CAG.ORF61 and CAG.ORF63. The CAG.VLT(ATA)-FLAG plasmid, in which the ATG start codon of VLT ORF

was mutated to ATA to prevent pVLT expression, was generated using primer VLT-G3A with a QuickChange Lightning Multi Site-Directed Mutagenesis kit (Agilent Technologies) according to the manufacturer's recommendation based on the CAG.VLT-FLAG. All primers used to construct VZV gene expression plasmids are listed in Supplementary Table 5. The pCAGGS plasmid (14) was generous gift from Dr. Jun-ichi Miyazaki (Osaka University, Japan). The pcDNA.ORF62 was a generous gift from Dr. Yasuyuki Gomi (Research Foundation for Microbial Diseases, Osaka University).

Generation of rabbit anti-pVLT and -IE63 antibodies

Anti-VLT protein (pVLT) antibody was generated by Sigma-Aldrich by immunizing a rabbit with a synthetic peptide encoding the first 19 amino acids of pVLT (MPRLLRDRIAGIPNRVRTY - Fig. S3). The antibody was purified using pVLT peptide conjugated NHS (N-hydroxysuccinimide)-activated sepharose (GE Healthcare Life Sciences). Anti-IE63 antibody was also generated by Sigma-Aldrich by immunizing a rabbit with GST-IE63 protein as described for anti-IE61 antibody⁴⁴. Briefly, GST-IE63 protein was expressed in and purified from *E. coli* BL21 transformed with pGEX-IE63, in which the entire DNA fragment except the first ATG (i.e. ORF63 nucleotide positions 4 - 837) was cloned into pGEX6P-1 bacterial expression vector (GE Healthcare). The anti-IE63 antibody was purified using GST-conjugated NHS-activated sepharose for depleting anti-GST antibody and GST-IE63-conjugated NHS-activated sepharose.

Immunofluorescent staining and confocal microscopy of cells

The following primary mouse monoclonal antibodies directed to the indicated proteins were used: VZV IE62 (clone 2-B; generous gift from Dr. Yasuyuki Gomi of Research Foundation for Microbial Diseases, Osaka University) and VZV glycoprotein E (clone 9)^{45,46} and anti-DYK

(FLAG tag; WAKO). Alexa Fluor 488- and Alexa Fluor 594-conjugated donkey-anti-rabbit and - anti-mouse IgG (Thermo Fisher Scientific) were used as secondary polyclonal antibodies, respectively. Hoechst 33342 (Sigma-Aldrich) was used for nuclear staining. Confocal microscopic analysis were performed as previously described⁴⁴.

Immunohistochemistry and immunofluorescence on human zoster skin biopsies

Deparaffinised and rehydrated 5 µm FFPE sections of human herpes zoster skin lesions and healthy control skin were subjected to heat-induced antigen retrieval with citrate buffer (pH=6.0), blocked and incubated with mouse anti-VZV IE63 (kindly provided by Dr. Sadzot-Delvaux; Liege, Belgium)⁴⁷, rabbit anti-pVLT or isotype control antibodies overnight at 4°C. Sections were subsequently incubated with biotinylated secondary goat-anti-rabbit Ig or goat-anti-mouse Ig and streptavidin-conjugated horseradish peroxidase (all from Dako) for 1 hr at room temperature. Signal was visualised using 3-amino-9-ethylcarbazole and counterstained with haematoxylin (Sigma-Aldrich). For immunofluorescent staining, Alexa Fluor 488- and Alexa Fluor 594-conjugated goat-anti-mouse and goat-anti-rabbit antibodies were used and sections were mounted with Prolong Diamond antifade mounting medium with DAPI. Confocal microscopic analysis was performed as described⁴⁸.

Plasmid co-transfection, comparison of viral gene expression by RT-qPCR and protein expression by immunoblotting

Plasmid co-transfection was performed using PEI_{max} (Mw 40,000) (Polysciences, Inc.). High potency linear polyethyleneimine was dissolved in water (1 mg/mL), adjusted to pH=7 with NaOH, filtered through an 0.22 µm filter and stored in aliquots at -20°C until use. CAG.Empty, CAG.VLT-FLAG, or CAG.VLT(ATA)-FLAG (2 µg) with CAG.ORF61, pcDNA.ORF62 and CAG.ORF63 (1 µg) were diluted in knockout DMEM/F12 media (Thermo Fisher Scientific) (50

μL) and PEI_{max} solution (6 μL) were diluted in knockout DMEM/F12 media (50 μL), then both diluent were mixed, left at room temperature for 10 to 15 min to form polyplexes and transfected into ARPE-19 cell (1x10⁵ cells/well in an 12-well plate). Culture medium was changed at 16 hrs post-transfection and cultured for another 48 hrs. Cells were harvested and aliquoted into two fractions. Total RNA extraction from one fraction of transfectants, cDNA synthesis and relative qPCR were performed as described in “Kinetic class of VZV transcripts” section using FavorPrep Blood/Cultured Cell Total RNA mini kit (FAVORGEN BIOTECH) instead of NucleoSpin RNA. The primer sets for VZV ORF62 (ORF62F2016 and ORF62R2083) and VLT (VLT_{exon2F} and VLT_{exon2R-2}) are presented in Supplementary Table 5. Immunoblotting was performed using a rabbit polyclonal antibody against VZV IE61 or IE63, and mouse monoclonal antibodies against alpha-tubulin (B-5-1-2; Sigma-Aldrich), VZV IE62 or FLAG tag (WAKO) for pVLT detection as described previously⁴⁴.

Data availability

All sequencing runs were performed using an Illumina NextSeq 550 and all demultiplexed fastq dataset are available via the European Nucleotide Archive (<http://www.ebi.ac.uk/ena>) under study accession PRJEB20723.

Supplementary references

31. Sadaoka, T., Yoshii, H., Imazawa, T., Yamanishi, K. & Mori, Y. Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts. *J. Virol.* 81, 12654–12665 (2007).
32. Ouwendijk, W. J. D. et al. Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells. *J. Immunol.* 192, 3730–9 (2014).
33. Lenac Roviš, T. et al. Comprehensive analysis of varicella-zoster virus proteins using a new monoclonal antibody collection. *J. Virol.* 87, 6943–54 (2013).

34. Sloutskin, A., Kinchington, P. R. & Goldstein, R. S. Productive vs non-productive infection by cell-free varicella zoster virus of human neurons derived from embryonic stem cells is dependent upon infectious viral dose. *Virology* 443, 285–293 (2013).
35. Krzywinski, M. et al. Circos: An information aesthetic for comparative genomics. *Genome Res.* 19, 1639–1645 (2009).
36. Rutherford, K. et al. Artemis: sequence visualization and annotation. *Bioinformatics* 16, 944–945 (2000).
37. Milne, I. et al. Tablet-next generation sequence assembly visualization. *Bioinformatics* 26, 401–402 (2009).
38. Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* (2014).
doi:10.1093/bioinformatics/btt656
39. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res.* (2013). doi:10.1093/nar/gkt214
40. Grabherr, M. G. et al. Full-length transcriptome assembly from RNA-Seq data without a reference genome. *Nat. Biotechnol.* 29, 644–52 (2011).
41. van Velzen, M. et al. Longitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIV. *J. Med. Virol.* 85, 1669–77 (2013).
42. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{(-Delta Delta C(T))}. *Method Methods* (2001).
43. Robinson, J. T. et al. Integrative genomics viewer. *Nat. Biotechnol.* (2011).
doi:10.1038/nbt.1754
44. Sadaoka, T. et al. Varicella-Zoster Virus ORF49 Functions in the Efficient Production of Progeny Virus through Its Interaction with Essential Tegument Protein ORF44. *J. Virol.* 88, 188–201 (2014).
45. Hama, Y. et al. Antibody to varicella-zoster virus immediate-early protein 62 augments

- allodynia in zoster via brain-derived neurotrophic factor. *J. Virol.* 84, 1616–24 (2010).
46. Okuno, T., Yamanishi, K., Shiraki, K. & Takahashi, M. Synthesis and Processing of Glycoproteins of Varicella-Zoster Virus (VZV) as Studied with Monoclonal Antibodies to VZV Antigens. *Virology* 129, 357–368 (1983).
 47. Kennedy, P. G., Grinfeld, E., Bontems, S. & Sadzot-Delvaux, C. Varicella-Zoster virus gene expression in latently infected rat dorsal root ganglia. *Virology* 289, 218–23 (2001).
 48. Ouwendijk, W. J. D. et al. T-Cell Tropism of Simian Varicella Virus during Primary Infection. *PLoS Pathog.* 9, (2013).